<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868868</url>
  </required_header>
  <id_info>
    <org_study_id>DC-990-0340</org_study_id>
    <nct_id>NCT00868868</nct_id>
  </id_info>
  <brief_title>Pedometer and Exercise Study in Prostate Cancer Patients With Hormonal Therapy</brief_title>
  <official_title>Pedometer and Exercise Study: A Randomized Trial Evaluating the Use of a Pedometer and Brief Exercise Coaching in Prostate Cancer Patients Treated With Androgen Deprivation Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe de recherche en Urologie de la Mauricie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe de recherche en Urologie de la Mauricie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized clinical trial evaluating the use of a pedometer and brief exercise coaching in&#xD;
      prostate cancer patients treated with androgen deprivation therapy. The investigators want to&#xD;
      demonstrate if there are less side effects of hormonal therapy and better quality of life in&#xD;
      patients who made regular exercise.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate effectiveness of regular exercise and well-being all patients will complete&#xD;
      questionnaires about sexual function (IIEF-15) and quality of life. We will also perform at&#xD;
      each visits anthropometrics measurement of waist, leg and arm, weight and vital signs.&#xD;
      Biochemical analysis and prostatic specific antigen will be done periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Prostate Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Male subjects aged 18 years or older with histological confirmed prostate cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Histologically proven prostate cancer&#xD;
&#xD;
          -  Treatment plan is to administer long term ADT (androgen deprivation therapy).&#xD;
&#xD;
          -  Patient must currently be treated with ADT for at least 2 weeks before enrollment in&#xD;
             trial, and for no more than 6 months. Patient treated with a maximum androgen blockade&#xD;
             strategy, combining an anti-androgen agent with a LHRH analog agent are admissible to&#xD;
             this protocol, but not patients treated only with an anti-androgen agent alone.&#xD;
&#xD;
          -  Written informed consent to participate in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to Zoladex, Casodex (if applicable), or any component of these&#xD;
             product, or to other similar agents&#xD;
&#xD;
          -  Severe cardiac disease (New York Heart Association class III or greater)&#xD;
&#xD;
          -  Severe lung disease&#xD;
&#xD;
          -  Uncontrollable pain&#xD;
&#xD;
          -  Unstable bone lesion&#xD;
&#xD;
          -  Any co-morbidity restraining the patient's ability to walk alone or to modify his&#xD;
             walking habits (eg Parkinson's disease, advanced multiple sclerosis, leg amputation,&#xD;
             ...)&#xD;
&#xD;
          -  Any concomitant condition that would make it undesirable, in the physician's opinion,&#xD;
             for the subject to participate in the trial or would jeopardize compliance with the&#xD;
             protocol.&#xD;
&#xD;
          -  Any contraindication to undertake the 6-minutes walk test (unstable angina or&#xD;
             myocardial infarction during the previous month, a resting heart rate of more than&#xD;
             180, systolic blood pressure of more than 180, and a diastolic pressure of more than&#xD;
             100). The patient must have his cardiovascular conditions stabilized and controlled&#xD;
             before enrollment in the trial.&#xD;
&#xD;
          -  Unwillingness or incapacity to consent to trial participation.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Alain Maillette, urologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe de recherche en Urologie de la Mauricie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Alain Maillette, urologist</last_name>
    <phone>819-373-4141</phone>
    <email>grum@cgocable.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe de Recherche en Urologie de la Mauricie</name>
      <address>
        <city>Trois-Rivi√®res</city>
        <zip>G9A 3V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Alain Maillette, Urologist</last_name>
      <phone>819-373-4141</phone>
      <email>grum@cgocable.ca</email>
    </contact>
    <investigator>
      <last_name>Dr Alain Maillette, Urologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <last_update_submitted>March 24, 2009</last_update_submitted>
  <last_update_submitted_qc>March 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr Alain Maillette</name_title>
    <organization>Groupe de Recherche en Urologie de la Mauricie</organization>
  </responsible_party>
  <keyword>Pedometer</keyword>
  <keyword>Prostate</keyword>
  <keyword>Cancer</keyword>
  <keyword>Hormonotherapy</keyword>
  <keyword>Exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

